XEXeris Biopharma Holdings, Inc. XERS · NASDAQ
$10.31 +2.38% (+$0.24)
- Market cap
- $1.74B
- Enterprise value
- $1.91B
- P/E
- -
- Forward P/E
- 1,925.3x
- PEG
- -
- P/S
- 5.2x
- P/FCF
- 31.4x
- EV/EBITDA
- 116.1x
- ROIC
- 12.5%
- Gross margin
- 83.3%
- Net margin
- -5.1%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 10.2x
- Beta
- 0.84
- Free float
- 94.9%
About the company
Xeris Biopharma Holdings, Inc. (XERS) is a biotechnology company focused on developing innovative therapeutic treatments for patients with metabolic disorders and endocrine diseases. Their main focus is on developing fixed-dose formulations of therapeutic drugs that can improve patients' quality of life and simplify their treatment regimen. Xeris Biopharma concentrates on areas such as diabetic hypoglycemia, type 1 and 2 diabetes, and adrenal insufficiency. The company is known for its innovative technologies in drug formulation and applications for patients with chronic conditions. Shares of Xeris Biopharma Holdings, Inc. (XERS) may be suitable for investors seeking opportunities in the biotechnology sector with potential for innovative treatments and growth prospects.
Sector
Healthcare
Industry
Biotechnology
CEO
John Shannon
Employees
435
Headquarters
Chicago
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number